Physician profile
Amy Wasterlain
NPI 1528402963
$90,537.73
in general payments reported to CMS, 2019-2025
14 companies · $2,120 in 2025
The $2,120 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $182 · 2021: $335 · 2022: $1,097 · 2023: $52K · 2024: $34K · 2025: $2,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Travel and Lodging: $16K · Food and Beverage: $5,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,200.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,750.00 |
| Travel and Lodging | $15,972.00 |
| Food and Beverage | $5,190.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $85,876.46 | 2020-2025 | Journey II, Real Intelligence, Legion Revision |
| Stryker Corporation | $3,834.87 | 2019-2025 | Mako, Triathlon, T2 |
| Zimmer Biomet Holdings, INC. | $219.62 | 2024-2025 | Persona, Rosa, Arcos |
| Davol INC. | $201.18 | 2022-2024 | |
| Depuy Synthes Sales INC. | $153.62 | 2019-2025 | Monovisc, Orthovisc |
| Vertex Pharmaceuticals Incorporated | $50.63 | 2024-2025 | |
| Bioventus LLC | $39.83 | 2020-2022 | |
| Endo Pharmaceuticals INC. | $36.51 | 2022-2023 | Xiaflex |
| Solventum Corporation | $25.55 | 2025 | V.A.C.Ulta, V.A.C. Veraflo Cleanse Choice, Prevena |
| Pacira Pharmaceuticals Incorporated | $23.38 | 2025 | Exparel, Zilretta, Iovera |
| Ibsa Pharma INC. | $21.70 | 2023 | Tirosint, Licart |
| Kerecis Limited | $20.15 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Urgo Medical North America, LLC | $19.26 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Fidia Pharma USA INC. | $14.97 | 2024 | Hyalgan, Triluron, Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wasterlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.